Patents Issued in March 2, 2017
  • MICRO/NANO COMPOSITE DRUG DELIVERY FORMULATIONS AND USES THEREOF
    Publication number: 20170056327
    Abstract: Disclosed are micro/nano composite drug delivery compositions for use in diagnosis, prophylaxis, treatment and/or amelioration of one or more symptoms of a mammalian disease, disorder, dysfunction, or abnormal condition. In illustrative embodiments, pharmaceutical formulations comprising these composites are provided that are useful in methods for targeting selected mammalian cells and tissues, particularly human lung tissue, and delivering one or more therapeutic agents, particularly in the treatment of human lung cancers, such as melanoma lung metastases.
    Type: Application
    Filed: August 25, 2016
    Publication date: March 2, 2017
    Inventors: Yu MI, Mauro FERRARI
  • Pharmaceuticals for Oral Delivery
    Publication number: 20170056328
    Abstract: The present invention provides pharmaceutical compositions suitable for oral delivery and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 2, 2017
    Inventors: Stephen M. Carl, John Stanley Vrettos, William Stern
  • Pharmaceutical Compositions for the Deterrence and/or Prevention of Abuse
    Publication number: 20170056329
    Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
    Type: Application
    Filed: May 3, 2016
    Publication date: March 2, 2017
    Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
  • MICROCAPSULE FORMULATION AND METHOD FOR PRODUCING THE SAME
    Publication number: 20170056330
    Abstract: [Object] An object of the present invention is to provide a method for producing a microcapsule formulation using a biodegradable polymer, the method being capable of avoiding direct contact of a peptidic physiologically active substance with an organic solvent layer, and achieving a high encapsulation efficiency of the peptidic physiologically active substance.
    Type: Application
    Filed: June 20, 2016
    Publication date: March 2, 2017
    Inventors: Yasuaki Ogawa, Naoki Tahara, Tomoya Yamashita, Shuzo Kojima, Felice Cheng, Sung-En Chen, Jui-Mei Lu
  • NOVEL DROPLET-EMBEDDED MICROFIBERS, AND METHODS AND DEVICES FOR PREPARING AND USING SAME
    Publication number: 20170056331
    Abstract: The invention includes microfluidic methods and devices that allow for the continuous production of microfibers with embedded droplets aligned along the length of the fiber at specific positions. The invention allows for formation of single or multiple emulsions within a fiber. The various phases comprised within the fiber can vary in terms of in terms of hydrophobic/hydrophilic character, solid/fluid, or gel crosslink density, which allows for the introduction of heterogeneous microenvironments within the fiber, each of which with distinct solubility characteristics, permeability, and mechanical properties. Various compounds and materials can be encapsulated in the different microcompartments of the fiber for storage and delivery applications, as well as to provide multifunctionality to the fiber structure.
    Type: Application
    Filed: April 7, 2015
    Publication date: March 2, 2017
    Inventors: Howard A. STONE, Janine K. NUNES, Eujin UM, Tamara PICO
  • HEMORRHOID PREPARATION AND SHEETS
    Publication number: 20170056332
    Abstract: A pharmaceutical composition for the treatment of hemorrhoids, sheets, methods of making and using the same.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 2, 2017
    Inventors: Nelson P. Ayala, Ping Qiu, Debanjan Das
  • DELIVERY OF ACTIVE AGENTS USING NANOFIBER WEBS
    Publication number: 20170056333
    Abstract: An active agent delivery system comprising a nanofiber web and an active agent carried by the nanofiber web.
    Type: Application
    Filed: August 31, 2016
    Publication date: March 2, 2017
    Inventors: Robert DiLuccio, Randy Milby
  • FAT-BASED FOOD PRODUCTS
    Publication number: 20170056334
    Abstract: The invention is in particular concerned with a food product comprising one or more fats or oils and a carotenoid compound. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation.
    Type: Application
    Filed: November 9, 2016
    Publication date: March 2, 2017
    Inventor: Ivan Petyaev
  • Ophthalmic Composition
    Publication number: 20170056335
    Abstract: The present invention provides an ophthalmic composition comprising polysorbate 80 and a refreshing agent, wherein a polydispersity of the polysorbate 80 in the ophthalmic composition is 1.00 to 1.26.
    Type: Application
    Filed: April 8, 2015
    Publication date: March 2, 2017
    Applicant: RHOTO PHARMACEUTICAL CO., LTD.
    Inventors: Masashi Itoh, Takenori Matsumoto, Chigusa Nakatsuka, Fumie Chono
  • CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
    Publication number: 20170056336
    Abstract: The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula (I), and/or their subgenra, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R8, R9, R11a, R11b, R11c, and R11d are as defined herein, and at least one therapeutically active agents selected from inhibitors of PI3K/AKT/mTOR pathway, active agents associated with the treatment of prostate cancer, and anticancer agents.
    Type: Application
    Filed: May 9, 2016
    Publication date: March 2, 2017
    Inventors: Marianne Dorothy SADAR, Jun WANG, Nasrin R. MAWJI, Minoru KATO
  • ANTIBACTERIAL S-HETEROSUBSTITUTED DISULFIDES
    Publication number: 20170056337
    Abstract: Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Francisella tularensis. The present invention provides compounds, methods and compositions effective to treat microbial/bacterial infections, and, especially, infections arising from bacteria which have developed resistance to conventional antibiotics.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Applicant: University of South Florida
    Inventors: Edward Turos, Praveen Ramaraju
  • Chocolate with antioxidants
    Publication number: 20170056338
    Abstract: A chocolate mixture comprising chocolate, preferably dark chocolate and an antioxidant mixture which includes: Ingredient Minimum Maximum Betacarotene 2000 IU 6000 IU Vitamin E Succinate 1185 IU/g 200 IU 400 IU Vitamin C 100 mg 400 mg Vitamin D3 200 IU 400 IU Vitamin K1 20 ?g 80 ?g Coenzyme Q10 20 mg 100 mg CURCUMAX?™ Curcumin Extract 100 mg 300 mg in Oil The antioxidant mixture makes up from about 4% to about 8% of the weight of the combination of chocolate and mixture. Other additives, such as fruit, nuts and candies may also be added, but their weight is not factored into the calculation of the relative proportion of chocolate to antioxidant mixture.
    Type: Application
    Filed: August 31, 2015
    Publication date: March 2, 2017
    Inventors: Herbert PARDELL, Mark J. PASULA, Paul J. MIANO
  • FORMULATION OF FAT-SOLUBLE VITAMIN
    Publication number: 20170056339
    Abstract: The invention relates to a composition comprising A) microcapsules comprising at least one fat-soluble active substance selected from a vitamin K compound or a provitamin or a prodrug of a vitamin K compound embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, and B) at least one dietary mineral; as well as uses and products comprising such compositions.
    Type: Application
    Filed: May 5, 2015
    Publication date: March 2, 2017
    Inventors: Inger Reidun AUKRUST, Helena M. LARSSON, Thomas ROVE
  • Composition for Administering an NMDA Receptor Antagonist to a Subject
    Publication number: 20170056340
    Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 2, 2017
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson, Seth Porter, Timothy S. Burkoth
  • Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
    Publication number: 20170056341
    Abstract: An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.
    Type: Application
    Filed: February 22, 2016
    Publication date: March 2, 2017
    Inventor: Bernard Charles Sherman
  • Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
    Publication number: 20170056342
    Abstract: An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.
    Type: Application
    Filed: August 31, 2015
    Publication date: March 2, 2017
    Inventor: Bernard Charles Sherman
  • Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
    Publication number: 20170056343
    Abstract: An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.
    Type: Application
    Filed: July 14, 2016
    Publication date: March 2, 2017
    Inventor: Bernard Charles Sherman
  • METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE
    Publication number: 20170056344
    Abstract: A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 2, 2017
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Bradley S. GALER
  • BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS
    Publication number: 20170056345
    Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.
    Type: Application
    Filed: February 18, 2015
    Publication date: March 2, 2017
    Inventors: Graham Timmins, Seong Won Choi
  • METHODS AND COMPOSITIONS FOR TREATING MULTIPLE MYELOMA
    Publication number: 20170056346
    Abstract: Methods and compositions for sensitizing multiple myeloma cells to treatment with IMiDs are provided. Aspects include methods of administering AR-42 and an IMiD (e.g., lenalidomide, pomalidomide) to multiple myeloma patients.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 2, 2017
    Inventors: Flavia Pichiorri, Craig Hoffmeister
  • METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES
    Publication number: 20170056347
    Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 2, 2017
    Inventors: Gary D. Glick, Luigi Franchi
  • Autoimmune Disorder Treatment using RXR Agonists
    Publication number: 20170056348
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 2, 2017
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Methods for Preventing or Reducing Colon Carcinogenesis
    Publication number: 20170056349
    Abstract: The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula I, IIa or IIb as disclosed herein.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 2, 2017
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Targeted Treatment of Anerobic Cancer
    Publication number: 20170056350
    Abstract: The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention.
    Type: Application
    Filed: August 5, 2016
    Publication date: March 2, 2017
    Inventors: John R. Haaga, Rebecca Haaga
  • COMPOSITION FOR INDUCING TUMOR IMMUNITY
    Publication number: 20170056351
    Abstract: [Problem to be Solved] It is an object of the present invention to provide a composition, which induces immunity to tumor cells and is also able to induce inhibition of tumor growth. [Solution] Provided is a composition for inducing tumor immunity, comprising ALAs.
    Type: Application
    Filed: February 19, 2015
    Publication date: March 2, 2017
    Inventors: Shigeru NISHIZAWA, Junkoh YAMAMOTO, Tohru TANAKA
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
    Publication number: 20170056352
    Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 2, 2017
    Inventors: Eduardo J. MARTINEZ, Andreas G. GRILL, Aniruddh SINGH, Padmini KAVURU
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF ss-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
    Publication number: 20170056353
    Abstract: The present invention relates to new pharmaceutical salts of ?-GPA which exhibit improved physical properties. In particular, the invention relates to salts of ?-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of ?-GPA, as well as methods of treating cancer including administration of a formulation including a ?-GPA salt of the invention to a subject in need thereof.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 2, 2017
    Inventors: Eduardo J. MARTINEZ, Andreas G. GRILL, Aniruddh SINGH, Padmini KAVURU
  • TYPE A GELATIN CAPSULE CONTAINING PUFA IN FREE ACID FORM
    Publication number: 20170056354
    Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
    Type: Application
    Filed: November 14, 2016
    Publication date: March 2, 2017
    Applicant: Chrysalis Pharma AG
    Inventors: Jean-Pierre SACHETTO, Roly BUFTON, Thomas BUSER
  • PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES
    Publication number: 20170056355
    Abstract: Pharmaceutical formulations containing lipoic acid derivatives are made.
    Type: Application
    Filed: April 21, 2016
    Publication date: March 2, 2017
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • UTILIZATION OF DIALKYL FUMARATES IN TREATMENT OF HEART FAILURE
    Publication number: 20170056356
    Abstract: Pharmaceutical preparations and methods for treating or preventing a heart failure disease, including heart failure with preserved ejection fraction (HFPEF), with one or more dialkyl fumarates alone or in combination with one or more second agents are provided herein. In some embodiments, the pharmaceutical preparations are in the form of micro-tablets or pellets.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 2, 2017
    Inventor: Vijaykumar Rajasekhar
  • METHOD OF DIETARY TREATMENT FOR GENETIC AND EPIGENETIC DISEASES AND DISORDERS
    Publication number: 20170056357
    Abstract: Genetic and epigenetic diseases and disorders are treated with FDA approved dietary compositions in the form of dietary supplements and nutraceuticals. The diseases and disorders to be treated include Rett syndrome, trinucleotide repeat diseases such as Fragile X syndrome, memory impairment, chronic inflammation, pre-cancerous conditions which involve cancer stem cells, and post-cancerous conditions which involve cancer stem cells which have survived in spite of cancer treatment. Treatment options include prophylactic treatment which is initiated prior to the development of the symptoms of the disease or disorder.
    Type: Application
    Filed: August 30, 2016
    Publication date: March 2, 2017
    Inventor: David Michael Ott
  • FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
    Publication number: 20170056358
    Abstract: Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
    Type: Application
    Filed: August 30, 2015
    Publication date: March 2, 2017
    Inventor: Mark Quang Nguyen
  • FUMARATE ESTER DOSAGE FORMS
    Publication number: 20170056359
    Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 2, 2017
    Inventors: Jason M. Vaughn, Justin R. Hughey, Tanesha Roberts, Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
  • FUMARATE ESTER DOSAGE FORMS
    Publication number: 20170056360
    Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
    Type: Application
    Filed: October 21, 2016
    Publication date: March 2, 2017
    Inventors: Jason M. Vaughn, Justin R. Hughey, Tanesha Roberts, Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
  • METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY
    Publication number: 20170056361
    Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Application
    Filed: October 25, 2016
    Publication date: March 2, 2017
    Inventor: Paresh Soni
  • SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION
    Publication number: 20170056362
    Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Inventors: Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
  • Method of lowering cholesterol
    Publication number: 20170056363
    Abstract: The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of ?-amyloid versus subjects without ?-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Inventor: Dayan Burke GOODENOWE
  • METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT
    Publication number: 20170056364
    Abstract: The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.
    Type: Application
    Filed: April 8, 2016
    Publication date: March 2, 2017
    Inventor: James E. Vath
  • DAPAGLIFLOZIN COMPOSITIONS
    Publication number: 20170056365
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of dapagliflozin and one or more pharmaceutically acceptable excipients, and processes for their preparation. It further relates to a method of treating diabetes using said pharmaceutical compositions.
    Type: Application
    Filed: February 27, 2015
    Publication date: March 2, 2017
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Suhani SINHA, Roshan Lal SANDAL, Ravi KOCHHAR
  • LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS
    Publication number: 20170056366
    Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 2, 2017
    Inventors: Claudius WEILER, Thomas DUCH, Marbod HAASE, Timothy Shane PRIDDY, Heike STETTLER
  • PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE OSTEOCLAST DIFFERENTIATION COMPRISING EUPATILIN
    Publication number: 20170056367
    Abstract: Disclosed is a pharmaceutical composition comprising eupatilin as an active ingredient for suppressing osteoclast differentiation, bone metastasis, and osteolysis and for preventing or treating periodontitis. Found to effectively inhibit the differentiation of osteoclast progenitors into osteoclasts and the fusion of mononucleated osteoclasts into multinucleated osteoclasts, and reduce the bone resorption of W multinucleated osteoclasts, Eupatilin is capable of effectively suppressing bone metastasis and osteolysis and may be used to prevent or treat periodontitis.
    Type: Application
    Filed: August 25, 2015
    Publication date: March 2, 2017
    Inventors: Byung Soo YOUN, Jae Min OH, Ju Young KIM, Myeung Su LEE
  • CANNABINOID COMPOSITIONS AND USES
    Publication number: 20170056368
    Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterized in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: Alex HEARN, Ritika GUPTA, Moira BOWDREY
  • TANNIN-CONTAINING GASTROINTESTINAL FORMULATIONS AND METHODS OF USE
    Publication number: 20170056369
    Abstract: Tannin-containing compositions and methods of using same to enhance or maintain immune function during simplified nutrition feeding. Pharmaceutical compositions, including enteral nutrition compositions, are provided. The compositions comprise such tannins as proanthocyanidins and/or hydrolysable tannins. Administering the tannins to the gastrointestinal tract of a subject receiving simplified nutrition, such as with enteral nutrition therapy or parenteral nutrition therapy, attenuates or prevents deleterious effects on the gastrointestinal immune system that would otherwise occur with the simplified nutrition.
    Type: Application
    Filed: November 9, 2016
    Publication date: March 2, 2017
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jess Dreher Reed, Dhanansayan Shanmuganayagam, Christian Gerald Krueger, Kenneth Allan Kudsk, Joseph Francis Pierre, Aaron F. Heneghan, Rodrigo P. Feliciano
  • COMPOSITION COMPRISING 7-HYDROXYMATAIRESINOL
    Publication number: 20170056370
    Abstract: A composition comprising 7-hydroxymatairesinol (HMR), or a stereoisomer, salt, complex, adduct or derivative thereof, or an extract containing them for preventing, alleviating or ameliorating the metabolic syndrome conditions.
    Type: Application
    Filed: May 13, 2015
    Publication date: March 2, 2017
    Applicant: LINNEA S.A.
    Inventors: Marcello LUZZANI, Massimiliano CARRERI
  • PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20170056371
    Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventor: Steven Hoffman
  • USE OF PRODRUGS OF FUMARATES IN TREATING HEART FAILURE DISEASES
    Publication number: 20170056372
    Abstract: Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 2, 2017
    Inventor: Vijaykumar Rajasekhar
  • GHRELIN O-ACYLTRANSFERASE INHIBITORS
    Publication number: 20170056373
    Abstract: Small molecule ghrelin O-acyltransferase inhibitors found using an assay to detect ghrelin O-acyltransferase activity using an acrylodan-labeled peptide mimic of ghrelin that provides for high-throughput screening for ghrelin O-acyltransferase inhibitors and detection via high performance liquid chromatography. The newly discovered class of synthetic triterpenoids efficiently inhibits ghrelin acylation by GOAT and function as covalent reversible inhibitors of GOAT. In cell studies, the most potent members of this family of compounds efficiently block ghrelin acylation at submicromolar concentrations and offer a foundation for continued development and evaluation of novel hGOAT inhibitors as therapeutics targeting disorders such obesity, type II diabetes, gastroparesis, and Prader-Willi syndrome.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 2, 2017
    Applicant: SYRACUSE UNIVERSITY
    Inventor: James Hougland
  • Fast Acting Orally Disintegrating Film
    Publication number: 20170056374
    Abstract: A fast acting orally disintegrating film (ODF) for treatment of various medical conditions including emesis that has a simple formulation, easy to manufacture and has similar pharmacokinetic profile to currently commercially available orally administered drug products is provided. The ODF comprises an active pharmaceutical ingredient such as ondansetron or a pharmaceutical acceptable salt thereof in an amount of 2 to 24 mg, at least one hydrophilic film forming polymer in an amount of at least 8% by weight of the film, wherein the at least one hydrophilic film forming polymer is characterized by having a molecular weight of 5000 to 50000 Da, and a water soluble excipient in an amount of 10 to 30% by weight of the film.
    Type: Application
    Filed: November 14, 2016
    Publication date: March 2, 2017
    Applicant: TAHO Pharmaceuticals Ltd.
    Inventors: Catherine Lee, Chien-Chiao Wang
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20170056375
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE
    Publication number: 20170056376
    Abstract: Benzoxazole and indole type KCa3.1 activators as well as the therapeutic uses of such compounds in human or animal subjects and their use in ex vivo preservation of organs or tissues.
    Type: Application
    Filed: April 24, 2015
    Publication date: March 2, 2017
    Inventors: Heike Wulff, Nichole Coleman, Brandon M. Brown, Aida Olivan-Viguera, Ralf Kohler